The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Efficacy of Eplerenone Added to Renin-Angiotensin Blockade in Hypertensive Patients
Open accessAbstract
The efficacy and tolerability of eplerenone, a selective aldosterone blocker, was assessed when added to existing antihypertensive therapy with an ACE inhibitor or an angiotensin II receptor blocker (ARB). Hypertensive patients (n=341) whose blood pressure (BP) was not controlled despite ACE inhibitor or ARB were randomized (double-blind) to receive 50 mg eplerenone (increasing to 100 mg if required) once daily or placebo for 8 weeks. Diastolic and systolic BP and adverse events were recorded. By study end (week 8), mean seated diastolic BP was significantly reduced from week 0 among patients receiving eplerenone/ARB (−12.7±0.81 mm Hg) compared with those receiving placebo/ARB (−9.3±0.83 mm Hg). The change in mean seated diastolic BP was −9.9±0.88 mm Hg in eplerenone/ACE inhibitor patients and −8.0±0.86 mm Hg in placebo/ACE inhibitor patients ( P =NS). Systolic BP levels were also significantly lower at week 8 for eplerenone/ACE inhibitor (−13.4±1.35 mm Hg) and eplerenone/ARB (−16.0±1.37 mm Hg) patients, respectively, compared with placebo/ACE inhibitor (−7.5±1.31 mm Hg) and placebo/ARB patients (−9.2±1.41 mm Hg). Adverse events were generally nonsevere and not significantly different between eplerenone and placebo. This study demonstrated that in patients whose BP was not controlled with an ACE inhibitor or ARB, the addition of eplerenone over an 8-week period significantly lowered systolic BP in both groups and diastolic BP in ARB patients. Selective aldosterone blockade with eplerenone, therefore, may be useful add-on therapy in hypertensive patients inadequately controlled on ACE inhibitor or ARB alone.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(1997) · Archives of Internal Medicine · doi:10.1001/archinte.1997.00440420033005 · Cited by 3,777
Staessen, J. A., Fagard, R., Thijs, L., Celis, H., Arabidze, G. G., Birkenhäger, W. H., Bulpitt, C. J., de Leeuw, P. W., Dollery, C. T., Fletcher, A. E., et al. (1997) · The Lancet · doi:10.1016/s0140-6736(97)05381-6 · Cited by 2,989
Cited by
Efficacy of low-dose spironolactone in subjects with resistant hypertension
Nishizaka, M. (2003) · American Journal of Hypertension · doi:10.1016/s0895-7061(03)01032-x · Cited by 502
Zeiger, M. A., Thompson, G. B., Duh, Q.-Y., Hamrahian, A. H., Angelos, P., Elaraj, D., Fishman, E., Kharlip, J., Zeiger, M. A., Thompson, G. B., et al. (2009) · Endocrine Practice · doi:10.4158/ep.15.s1.1 · Cited by 499
The renin-angiotensin-aldosterone system and its suppression
Ames, M. K., Atkins, C. E., & Pitt, B. (2019) · Journal of Veterinary Internal Medicine · doi:10.1111/jvim.15454 · Cited by 433
Parthasarathy, H. K., Ménard, J., White, W. B., Young, W. F., Williams, G. H., Williams, B., Ruilope, L. M., McInnes, G. T., Connell, J. M., & MacDonald, T. M. (2011) · Journal of Hypertension · doi:10.1097/hjh.0b013e3283455ca5 · Cited by 281
Mottram, P. M., Haluska, B., Leano, R., Cowley, D., Stowasser, M., & Marwick, T. H. (2004) · Circulation · doi:10.1161/01.cir.0000138680.89536.a9 · Cited by 278
Metadata
- Authors
- Krum, H., Nolly, H., Workman, D., He, W., Roniker, B., Krause, S., & Fakouhi, K.
- Venue
- Hypertension
- Published
- 2002-08
- Volume
- 40
- Issue
- 2
- Pages
- 117-123
- ISSN
- 0194-911X (ISSN-L)
- 1524-4563
- OpenAlex
- W2116965552
- Cited by
- 210
- References
- 2
- FWCI
- 15.58
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Efficacy of Eplerenone Added to Renin-Angiotensin Blockade in Hypertensive Patients. https://app.cochat.ai/papers/10.1161/01.hyp.0000025146.19104.fe
- The paper
- Krum, H., Nolly, H., Workman, D., He, W., Roniker, B., Krause, S., & Fakouhi, K. (2002). Efficacy of Eplerenone Added to Renin-Angiotensin Blockade in Hypertensive Patients. Hypertension. https://doi.org/10.1161/01.hyp.0000025146.19104.fe
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.